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Abstract
Background: Combination vaccines improve coverage, compliance and effectively introduce new antigens to mass
vaccination programmes. This was a phase III, observer-blind, randomized study of GSK Biologicals diphtheria-
tetanus-whole cell pertussis vaccine combined with hepatitis B and Haemophilus influenzae type b vaccines,
containing a reduced amount of polyribosyl-ribitol-phosphate (PRP) and a DTPw component manufactured at a
different site (DTPw-HBV/Hib2.5 [Kft]). The primary aim of this study was to demonstrate that DTPw-HBV/Hib2.5 [Kft]
was not inferior to the licensed DTPw-HBV/Hib (Tritanrix(tm)-HepB/Hiberix(tm)) vaccine or the DTPw-HBV/Hib2.5
vaccine, also containing a reduced amount of PRP, with respect to the immune response to the PRP antigen,
when administered to healthy infants, according to the Expanded Programme for Immunization (EPI) schedule at 6,
10 and 14 weeks of age.
Methods: 299 healthy infants were randomised to receive either DTPw-HBV/Hib2.5 [Kft] DTPw-HBV/Hib2.5 or DTPw-
HBV/Hib according to the 6-10-14 week EPI schedule. Blood samples were analysed prior to the first dose of study
vaccine and one month after the third vaccine dose for the analysis of immune responses. Solicited local and general
symptoms such as pain, redness and swelling at the injection site and drowsiness and fever, unsolicited symptoms
(defined as any additional adverse event) and serious adverse events (SAEs) were recorded up to 20 weeks of age.
Results: One month after the third vaccine dose, 100% of subjects receiving DTPw-HBV/Hib2.5 [Kft] or DTPw-HBV/
Hib and 98.8% of subjects receiving DTPw-HBV/Hib2.5 vaccine had seroprotective levels of anti-PRP antibodies
(defined as anti-PRP antibody concentration ≥0.15 μg/ml). Seroprotective antibody concentrations were attained in
over 98.9% of subjects for diphtheria, tetanus and hepatitis B. The vaccine response rate to pertussis antigen was at
least 97.8% in each group. Overall, the DTPw-HBV/Hib2.5 [Kft] vaccine was well tolerated in healthy infants; no SAEs
were reported in any group.
Conclusions: The DTPw-HBV/Hib2.5 [Kft] vaccine was immunogenic and well-tolerated when administered
according to the EPI schedule to Indian infants.
Trial registration: http://www.clinicaltrials.gov NCT00473668.
Background
Combination vaccines improve individual compliance
and vaccination coverage and offer a convenient vehicle
for introducing community protection against new dis-
eases by adding antigens to an existing vaccine with
high coverage [1,2]. The diphtheria-tetanus-whole cell
pertussis (DTPw) is one such vaccine, with a global cov-
erage of 81% in 2007 [3].
In 1996, GlaxoSmithKline (GSK) Biologicals licensed
the first combined DTPw and hepatitis B vaccine
(DTPw-HBV, Tritanrix(tm)Hep B), which was shown to
improve the uptake of hepatitis B vaccine in Thailand [4].
Haemophilus influenzae type b (Hib) protection was
added via the monovalent vaccine, Hiberix(tm) to form
DTPw-HBV/Hib. This combination vaccine facilitated
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large parts of the developing world [5].
Increasing global demands for DTPw-based combina-
tion vaccines has necessitated creative strategies to ensure
the adequate supply of the vaccine antigens, through redu-
cing Hib antigen content and expanding antigen produc-
tion at new manufacturing sites. Primary vaccination with
reduced Hib content vaccines has been shown to confer
vaccine response rates, after primary vaccination, at least
as high as those observed with commercially available
DTPw-HBV/Hib containing 10 μg PRP [6,7]. DTPw-HBV/
Hib2.5, which contains a reduced amount of the purified
polyribosyl-ribitol-phosphate capsular polysaccharide
(PRP) of Hib covalently bound to tetanus toxoid has been
subsequently developed. Furthermore, a formulation of
this vaccine [(DTPw-HBV/Hib2.5 [Kft]; Zilbrix(tm)-Hib)]
manufactured at a new production site in Hungary and
represented by ‘Kft’ has been introduced.
The primary aim of this study was to demonstrate that
(DTPw-HBV/Hib2.5 [Kft]) was not inferior to the licensed
DTPw-HBV/Hib (Tritanrix(tm)-HepB/Hiberix(tm)) vac-
cine or the DTPw-HBV/Hib2.5 vaccine with respect to
the immune response to the PRP antigen, when adminis-
tered to healthy infants according to the Expanded Pro-
gramme for Immunization (EPI) schedule at 6, 10 and
14 weeks of age. The DTPw-HBV/Hib2.5 [Kft] differs
from the other two vaccines in the study as it has compo-
nents manufactured at a site in Hungary.
Methods
Study design and subjects
This phase III, observer-blind, randomized, primary
vaccination study took place at three centres in India
between June 2007 and January 2008. The trial followed
the principles of the Declaration of Helsinki, and was
compliant with the international standards of Good
Clinical Practice and the local Indian Council of Medical
Research guidelines governing clinical trials [8]. The
study protocol was approved by the office of the Drugs
Controller General of India (DCGI). The protocol was
also subject to an institutional ethics committee review
at each centre. Additionally, the study processes were
subject to a sponsor audit without any critical findings.
Written, informed consent was obtained from parents/
guardians before enrolment. Healthy infants aged 6-8
weeks who had received one dose of the Hep B vaccine
within one week of birth were randomised to receive
the DTPw-HBV/Hib2.5 [Kft], DTPw-HBV/Hib2.5 or
DTPw-HBV/Hib vaccines at 6, 10 and 14 weeks of age
by intramuscular injection in the thigh.
Vaccines
The diphtheria and tetanus antigens of the DTPw-HBV/
Hib2.5 [Kft] vaccine were produced at GSK Biologicals,
Korlatolt Felelossegu Tarsasag in Hungary, all other
components of this, and the other vaccines, were devel-
oped and manufactured by GSK Biologicals, Rixensart,
Belgium. The pertussis components were produced by
the Commonwealth Serum Laboratory in Australia.
All vaccines contained: at least 30 international units
(IU) of diphtheria toxoid, 60 IU of tetanus toxoid and 4
IU of Bordetella pertussis (BPT), killed; and 10 μgo f
hepatitis B surface antigen (HBsAg). The study vaccine,
DTPw-HBV/Hib2.5 [Kft] and the comparator DTPw-
HBV/Hib2.5 both contained 2.5 μgo ft h eH. influenzae
type b capsular polysaccharide conjugated to 5-10 μgo f
the tetanus toxoid, compared to 10 μg of the H. influen-
zae type b capsular polysaccharide conjugated to 20 to
40 μg tetanus toxoid in the DTPw-HBV/Hib vaccine.
Assessment of immunogenicity
Blood samples were collected before the first dose of
study vaccine and one month after the third vaccine
dose and were tested for antibodies against all vaccine
antigens, using enzyme-linked immunosorbent assays
(ELISAs).
Anti-PRP antibodies were measured by ELISA with a
cut-off set at 0.15 μg/ml. Anti-diphtheria and anti-tetanus
antibody concentrations were measured by ELISA with an
assay cut-off set at 0.10 IU/ml. Subjects seronegative for
anti-diphtheria antibodies by ELISA were re-tested with
an in vitro neutralization assay on Vero cells (cut-off of
0.016 IU/ml). Anti-HBs antibodies were determined using
either a commercial radioimmunoassay (AUSAB, Abbott),
an ELISA developed in house or combination of the two,
with an assay cut-off set at 10 mIU/ml. Seroprotection was
defined as antibody concentrations greater or equal to the
assay cut-off. Anti-whole-cell-Bordetella Pertussis (BPT)
antibody concentrations were measured by ELISA (Ani-
Labsystems) with an assay cut-off set at 15 ELU/ml.
Assessment of Reactogenicity
Reactogenicity was assessed using diary cards during a
4-day follow-up period after each vaccination. Reports
of local symptoms of pain, redness and swelling at the
site of injection, and of general symptoms of drowsiness,
fever (defined as an axillary temperature ≥37.5°C), irrit-
ability and loss of appetite were actively solicited. Symp-
tom intensities for pain, irritability, drowsiness and loss
of appetite were graded by the investigators on a three
point scale. Grade 3 was defined as: cries when limb is
moved/spontaneously painful (pain); diameter > 20 mm
(swelling and redness); interfering with normal activities
(other symptoms).
Unsolicited symptoms were recorded during the
30-day follow-up period after each vaccine dose and ser-
ious adverse events (SAE) were recorded throughout the
duration of the trial.
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The primary objective of the study was to sequentially
assess and check the non-inferiority of the DTPw-HBV/
Hib2.5 [Kft] vaccine versus first DTPw-HBV/Hib and
then DTPw-HBV/Hib2.5, in terms of the anti-PRP anti-
body response, after a three-dose primary vaccination
course administered to healthy infants at 6, 10 and 14
weeks of age.
The analysis of immunogenicity was based on the
according to protocol (ATP) cohort for analysis of
immunogenicity, which included all evaluable subjects
for whom at least one measurement for the immuno-
genicity endpoint measures were available and who fol-
lowed the study procedures. Evaluable subjects were
those that met all the eligibility criteria, complied with
the procedures defined in the protocol and were not
eliminated from the study.
It was calculated that a sample size of 90 evaluable
subjects per group would provide an overall power of
92% to meet the non-inferiority criteria for both the pri-
mary endpoints assuming the groups elicited identical
immune responses. Allowing for an attrition rate of
1 0 % ,at a r g e ts a m p l es i z eo f3 0 0s u b j e c t s( 1 0 0s u b j e c t s
per vaccine group) was selected.
Antibody seroprotection rates were calculated with
95% confidence intervals (CIs) one month after the third
vaccine dose. Geometric mean concentrations (GMCs)
were calculated by taking the anti-log of the mean of
the log concentration transformations. Antibody con-
centrations below the cut-off of the assay were given an
arbitrary value of half the cut-off for the purpose of
GMC calculation. As there is no established correlate of
protection against pertussis, a vaccine response was
defined as the appearance of antibodies in initially sero-
negative subjects, or maintenance or increase of pre-
vaccination antibody concentrations in subjects that
were seropositive prior to vaccination, taking into
account the decline of maternal antibodies. All CIs cal-
culated were 2-sided and computed using Proc StatXact
SAS 9.1 and Proc StatXact 5 procedure on SAS. Non-
inferiority was considered to be reached if the upper
limit of the two-sided 95% CI, for the differences in the
percentage of subjects with anti-PRP antibody concen-
trations of ≥0.15 μg/ml, was below the pre-defined limit
of 10% one month after the 3
rd vaccine dose. Additional
exploratory analyses of seroprotection using 95% CI on
differences in seroprotection or vaccine response rates
or ratios of GMCs between the study vaccine and com-
parator groups were undertaken.
The safety analysis was based on the Total Vaccinated
Cohort. The incidence of solicited local and general
adverse events (any or grade 3 intensity) was calculated
using exact 95% CI. Exploratory analyses were used to
compare the incidence of solicited symptoms between the
groups. The standardized asymptotic 95% CI for the differ-
ence between groups was also computed (StatXact 7) for
the occurrence of solicited symptoms (during the 4-day
follow-up period) after each vaccine dose, and overall per
dose and per subject. CIs excluding zero indicated that a
difference between groups may exist.
Results
A total of 300 subjects were recruited, of whom 299
subjects were vaccinated and included in the total vacci-
nated cohort and 267 were included in the ATP immu-
nogenicity cohort of subjects (Figure 1). There were no
withdrawals due to adverse events and 273 subjects
completed the study. The demographic characteristics of
the subjects in the three groups were similar (Table 1).
Immunogenicity
One month after the third vaccine dose, all subjects
vaccinated with DTPw-HBV/Hib2.5 [Kft] and DTPw-
HBV/Hib and 98.8% of those vaccinated with DTPw-
HBV/Hib2.5 had seroprotective levels of anti-PRP anti-
bodies across all three groups (Table 2). The upper limit
of the 95% CI for the difference between groups in the
percentage of subjects with seroprotective anti-PRP anti-
body concentrations (≥0.15 μg/ml) was below the pre-
defined limit of 10%. Thus the study vaccine, DTPw-
HBV/Hib2.5 [Kft], was shown to be non-inferior to the
two comparator vaccines.
In all three groups, seroprotective antibody concentra-
tions were attained in 100% of subjects for diphtheria,
tetanus and hepatitis B one month after the vaccination
course. The vaccine response rate to the pertussis com-
ponent, at the same time point, was at least 97.8% in
each group (Table 3).
Additional exploratory analyses also indicated the
non-inferiority of DTPw-HBV/Hib2.5 [Kft] to DTPw-
HBV/Hib and DTPw-HBV/Hib2.5 in terms of seropro-
tection rates to diphtheria, tetanus and HepB antigens
and of vaccine response to the pertussis component.
Non-inferiority of DTPw-HBV/Hib2.5 [Kft] to DTPw-
HBV/Hib2.5 was also demonstrated for antibody GMCs
to diphtheria, tetanus, HepB and PRP antigens and for
DTPw-HBV/Hib2.5 [Kft] compared to DTPw-HBV/Hib
with respect to antibody GMCs to the diphtheria, teta-
nus and hepatitis B antigens.
Safety
Pain was the most frequently observed local solicited
symptom during the 4-day follow-up period (Figure 2).
Analysis per subject showed that fever was the most fre-
quently observed solicited general symptom for DTPw-
HBV/Hib2.5 [Kft] (80.2%) and DTPw-HBV/Hib2.5
(76.0%) subjects, while irritability was the most fre-
quently observed solicited general symptom for DTPw-
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Page 3 of 8Table 1 Summary of demographic characteristics (Total Vaccinated Cohort)
DTPw-HBV/Hib2.5 [Kft] (N = 100) DTPw-HBV/Hib (N = 99) DTPw-HBV/Hib2.5 (N = 100) Total (N = 299)
Characteristics Value or n % Value or n % Value or n % Value or n %
Age (weeks) Mean 6.3 - 6.3 - 6.4 - 6.3 -
SD 0.59 - 0.51 - 0.64 - 0.58 -
Weight (kg) Mean 3.9 - 3.9 - 3.8 - 3.9 -
SD 0.69 - 0.66 - 0.70 - 0.69 -
Gender Female 39 39.0 37 37.4 48 48.0 124 41.5
Male 61 61.0 62 62.6 52 52.0 175 58.5
Race Asian 100 100.0 99 100.0 100 100.0 299 100.0
N = total number of subjects; n/% = number/percentage of subjects in a given category; SD = standard deviation.
Figure 1 Distribution of subjects (CONSORT diagram).
Table 2 Anti-PRP antibody response before dose 1 (pre) and one month post-dose 3 (post; ATP cohort for
immunogenicity)
Time point ≥0.15 μg/mL ≥1.0 μg/mL GMC
N % 95% CI % 95% CI Value 95% CI
DTPw-HBV/Hib2.5 [Kft] Pre 93 44.1 33.8-54.8 9.7 4.5-17.6 0.179 0.139-0.230
Post 93 100 96.1-100 94.6 87.9-98.2 26.71 19.161-37.23
DTPw-HBV/Hib Pre 89 42.7 32.3-53.6 10.1 4.7-18.3 0.177 0.137-0.227
Post 89 100 95.9-100 100 95.9-100 40.75 32.301-51.40
DTPw-HBV/Hib2.5 Pre 84 42.9 32.1-54.1 8.3 3.4-16.4 0.167 0.131-0.212
Post 85 98.8 93.6-100 94.1 86.8-98.1 19.58 14.019-27.36
N = total number of subjects; CI = confidence interval; GMC = geometric mean concentration.
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Page 4 of 8Table 3 Seroprotection rates and GMCs for diphtheria, tetanus, HBV and pertussis before dose 1 (pre) and one month post-dose 3 (post; ATP cohort for
immunogenicity)
Seroprotection rates/Vaccine response rates GMC
DTPw-HBV/Hib2.5 [Kft] DTPw-HBV/Hib DTPw-HBV/Hib2.5 DTPw-HBV/Hib2.5 [Kft] DTPw-HBV/Hib DTPw-HBV/Hib2.5
Time point N % 95% CI N % 95% CI N % 95% CI Value 95% CI Value 95% CI Value 95% CI
Diphtheria ≥0.1 IU/ml (or
≥0.016 IU/ml by
neutralization assay)
Pre 93 31.2 22.0-41.6 89 34.8 25.0-45.7 85 24.7 16.0-35.3 0.086 0.070-0.105 0.082 0.069-0.097 0.076 0.063-0.093
Post 93 100 96.1-100 89 98.9 95.9-100 85 100 95.8-100 2.89 2.30-3.64 1.76 1.41-2.19 1.65 1.36-2.02
Tetanus ≥0.1 IU/ml Pre 93 100 96.1-100 89 100 95.9-100 85 100 95.8-100 1.950 1.561-2.437 2.416 1.991-2.932 2.112 1.751-2.548
Post 93 100 96.1-100 89 100 95.9-100 85 100 95.8-100 4.74 3.78-5.95 2.82 2.32-3.45 2.77 2.24-3.44
HBV ≥10 mIU/ml Pre 85 25.9 17.0-36.5 85 24.7 16.0-35.3 84 21.4 13.2-31.7 8.3 6.7-10.3 8.0 6.5-9.8 6.6 5.8-7.5
Post 92 100 96.1-100 89 100 95.9-100 85 100 95.8-100 781.1 629.7-968.8 598.2 477.7-749.1 695.3 542.1-891.7
Anti-BPT antibodies ≥15 El.
U/ml
Pre 93 16.1 9.3-25.2 89 19.1 11.5-28.8 85 22.4 14.0-32.7 9.1 8.2-10.1 9.1 8.3-10.0 9.8 8.7-11.0
Post 93 98.9 94.2-100 89 98.9 93.9-100 85 100 95.8-100 63.4 55.4-72.7 83.7 73.6-95.2 100.3 88.4-113.7
VR for anti-BPT antibody Post 93 97.8 92.4-99.7 89 98.9 93.9-100 85 98.8 93.6-100
BPT = Bordetella pertussis; CI = confidence interval; GMC = geometric mean concentration; HBV = hepatitis B vaccine; IU = international unit; N = number of subjects with available results; VR = vaccine response.
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8HBV/Hib (64.2%). A higher overall incidence of grade 3
adverse events was observed in the DTPw-HBV/Hib2.5
[Kft] group.
The percentage of subjects reporting at least one
unsolicited symptom within the 31 day follow up period
after the administration of any vaccination dose was less
than 6% in any of the groups. None of the subjects
reported grade 3 unsolicited symptoms related to
vaccination.
No SAEs were reported in any of the groups.
Discussion
Vaccination of Indian infants against diphtheria, tetanus
and pertussis is recommended according to the EPI
schedule at 6, 10 and 14 weeks [9]. In addition, the
Indian Academy of Pediatrics and WHO [10] recom-
mend a birth dose of HBV to reduce the vertical trans-
mission of hepatitis B to newborns, as well as HBV
priming doses at the EPI time points. In 2006, WHO
recommended the worldwide incorporation of Haemo-
philus influenzae type b vaccination into all routine
infant immunization programs from as early as possible
after 6 weeks of age [11]. In India Hib priming doses at
the EPI time points are recommended.
Co-administration of multiple antigens in a single
injection is widely accepted as beneficial with respect to
convenience, compliance and timeliness of vaccination
[1,2,12]. With respect to the DTPw-HBV-Hib vaccines,
many clinical studies have shown that the five antigens
can be co-administered without impacting upon the
immunogenicity of the individual components [13]. The
combination vaccine, DTPw-HBV-Hib, containing 10 μg
PRP was licensed for primary and booster immunization
of Indian infants in 2000 and has been locally shown to
be immunogenic and well tolerated [14].
This trial studied the administration of the DTPw-
HBV/Hib2.5 [Kft] vaccine according to the challenging
6-10-14 week EPI schedule, with prior administration of
a birth dose of HBV, as recommended locally by the
IAP and the WHO.
All subjects were seroprotected against Hib,
diphtheria, tetanus and HBV one month after the third
dose and 97.8% subjects showed a vaccine response to
pertussis. These findings are similar to those achieved
by the licensed vaccine, and comparable to levels
previously reported in studies using these pentavalent
vaccines in an Asian population [5,6,14-16]. Our study
demonstrated DTPw-HBV/Hib2.5 [Kft] to be non-
inferior in terms anti-PRP antibody response compared
to both DTPw-HBV/Hib vaccine and DTPw-HBV/Hib2.5
vaccine after a three-dose primary vaccination course.
However, the anti-PRP GMC point estimate for the
comparator DTPw-HB/Hib2.5 vaccine (which, unlike the
other 2 vaccines [Tritanrix(tm)-HepB/Hiberix(tm) and
Zilbrix-Hib(tm)] used in this study, is not a WHO pre-
qualified) vaccine [17,18] was significantly lower than
for the full-content DTPw-HB/Hib. The results from
this study agree with previous findings from the
Figure 2 Incidence of solicited local and general adverse events, within 4 days of vaccination after all doses (Total Vaccinated Cohort).
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Page 6 of 8Philippines and Latina comparing a DTPw-HB/Hib2.5
vaccine with the licensed vaccine [6,19] and support the
observation that vaccines containing reduced amounts
of PRP-tetanus toxoid conjugate generate effective anti-
body responses and immunological protection
[16,7,20-26]. The responsest ot h eo t h e ra n t i g e n so f
DTPw-HBV/Hib2.5 [Kft] were also found to be within
similar 95% confidence intervals as the other vaccines,
in terms of seroprotection and vaccine response, further
substantiating the non-inferiority of the DTPw-HBV/
Hib2.5 [Kft] vaccine to the two comparator vaccines.
Overall, the safety profile of the new DTPw-HBV/
Hib2.5 [Kft] vaccine appeared to be similar to that of the
licensed comparator vaccines and the incidence of
symptoms reported was within the range of incidences
reported in the literature after DTPw-based combination
vaccines [5].
This study was designed to assess primary vaccination at
6, 10 and 14 weeks. In clinical practice an additional boos-
ter dose of the vaccine is recommended at 12-18 months.
Although a booster was not included in this study, the
vaccine was immunogenic (seroprotection above accepted
minimum cut-off values) following the primary vaccina-
tion course. The non-inferiority analysis was not per-
formed on the PRP cut-off ≥1.0 μg/mL, as the study was
not powered for this comparison, although this concentra-
tion is regarded as an indicator of long-term protection.
Nevertheless, the CIs for the percentage of subjects sero-
protected overlapped (at least 94.1% in all groups) indicat-
ing that all three vaccines conferred long-term protection.
In addition, The Hib immune response to the DTPw-
HBV/Hib2.5 [Kft] was similar to that observed with
another, WHO prequalified, DTPw-HBV-Hib vaccine
administered in a 2-3-4 month schedule [27].
Reduction of the antigen content of the Hib compo-
nent of DTPw-HBV/Hib and the different formulation of
the DTPw-HBV/Hib2.5 [Kft] DTPw antigens did not have
any significant effects on the safety, reactogenicity and
immunogenicity parameters tested of the combination
vaccine when compared to the licensed comparator vac-
cines. However, further studies need to be carried out to
assess any interference on other vaccines, which may be
co-administered at the EPI time points, such as rotavirus
vaccine or conjugated pneumococcus vaccine.
Conclusions
The reduced PRP, new formulation, DTPw-HBV/Hib2.5
[Kft] vaccine was immunogenic and well tolerated when
administered according to the EPI schedule to Indian
infants. It was also shown to be non-inferior to DTPw-
HBV/Hib and DTPw-HBV/Hib2.5 in terms of seropro-
tection rates to diphtheria, tetanus and HepB antigens
and of vaccine response to the pertussis component.
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